Clavis Pharma
11
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
9%
1 trials in Phase 3/4
0%
0 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)
Role: lead
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
Role: lead
The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)
Role: lead
A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies
Role: lead
A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer
Role: lead
Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma
Role: lead
Elacytarabine Mass Balance Study in Healthy Volunteers
Role: lead
A Study of CP-4126 in Patients With Advanced Pancreatic Cancer
Role: lead
A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour
Role: lead
A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer
Role: lead
Clinical Study of Previously Untreated Patients With Malignant Melanoma
Role: lead
All 11 trials loaded